|
|
Article: AVANIR Obtains First European Marketing Approval for Docosanol 10% Cream for Cold Sores; Sweden is Lead Country in European Mutual Recognition Process.
- Article from:
- Business Wire
- Article date:
- November 19, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
BIOWIRE2K
SAN DIEGO--(BUSINESS WIRE)--Nov. 19, 2003
Marketed in U.S. by GlaxoSmithKline as Abreva(R), Additional
European Partners To Be Selected
AVANIR Pharmaceuticals (AMEX:AVN) said the Swedish Medical Products Agency approved docosanol 10% cream (known in the U.S. as Abreva(R)) for marketing as a non-prescription, over-the-counter topical treatment for cold sore infections.
Sweden will act as AVANIR's Reference Member State for the mutual recognition process within Europe. AVANIR intends to license the product to partners for marketing in Europe and has already announced ...